Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of PTX-COVID19-B Vaccine in Healthy Adults
NCT04765436Phase 1Completed
- Sponsor
- Providence Therapeutics
- Start
- Jan 2021
- Primary completion
- Mar 2022
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in coronavirus disease 2019 (COVID-19) comparing PTX-COVID19-B with Placebo (2 arms). Primary endpoints: Occurrence of adverse events, Assessments of adverse events and 2 more. Started Jan 2021; status: completed.
02
Drugs
PTX-COVID19-B
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04765436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04765436.